IDegLira, LixiLan go head-to-head; FDA approves Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day.

Therapy shows neutral CV benefit, increases bleeding risk in type 2 diabetes.

Study finds treatment on top of stable renin angiotensin system (RAS)-inhibition decreased risk.

Study shows death rate more than five times higher than in those without the disease.

Organizations publish recommendations for identifying and reporting hypoglycemia in clinical studies.

Transcript: Dr. Richard Bergenstal, endocrinologist and an executive director of the International Diabetes Center at Park Nicollet, discusses hybrid closed-loop technology.

Video: Diabetes in Control Publisher Steve Freed talks with Dr. Richard Bergenstal about his work on the hybrid closed-loop system, the first of its kind to be awarded approval by the FDA.

How comfortable are you in recommending the combination of a GLP-1 receptor agonist along with glargine insulin? 1- Very comfortable 2- Slightly comfortable 3- Neutral 4- Slightly uncomfortable 5- Very uncomfortable at this time Follow the link to share your response and see what your colleagues think!

Please select the drug class that best fits the description. This injectable drug class leads to increased insulin secretion, decreased glucagon secretion and slowed gastric emptying. One of its advantages is that its use can lead to weight loss: 1. DPP-4 inhibitors 2. GLP-1 receptor agonists 3. Dopamine-2 Agonists 4. SGLT-2 Inhibitors Did you get it right? Follow the link to find out!

It has been 10 years since Sitagliptin was approved by the FDA. When it was first approved there was a lot of pushback from prescribers to trying a new class, as the last class, the TZDs, had suffered through the problems with Rezulin and the cardiovascular problems associated with Actos …